Goodman & Nekvasil, P.A., May Recover Investor Losses – Edge Therapeutics (EDGE)
Edge Therapeutics (EDGE) is a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions.
CNBC reports that a lawsuit has been filed against Edge Therapeutics (EDGE) alleging that Edge Therapeutics (EDGE) made materially false and misleading statements during the class period. The complaint further alleges that Edge Therapeutics (EDGE) failed to disclose that the company’s leading new product candidate, known as EG-1962, was likely to fail a futility test related to the NEWTON 2 study. According to the complaint, as a result of the failure to disclose this information, Edge Therapeutics’ financial statements, claims about the company’s business operations, and financial prospects were materially false and misleading throughout the class period. According to the lawsuit, when accurate information about Edge Therapeutics became apparent in the market, investors suffered damages.
Goodman & Nekvasil, P.A., a Clearwater, Florida, law firm with a national practice representing victimized investors, continues to investigate brokerage firms that placed elderly retirees and other conservative investors in high-risk investments such as Edge Therapeutics (EDGE).
Goodman & Nekvasil, P.A., has filed hundreds of cases against brokerage firms selling high-risk investments such as Edge Therapeutics (EDGE) and has recovered more than $180 million dollars on behalf of victimized investors. We allege in these cases that these investment recommendations were unsuitable for our clients in view of their financial situation, needs and investment objectives. All our cases are handled on a purely contingency fee basis.
You may have the right to recover your losses from the brokerage firm that sold Edge Therapeutics (EDGE) and other high-risk investments to you. We strongly recommend that you act quickly, however, because statutes of limitation can be short in securities cases.
Kalju Nekvasil, Esq., formerly regional counsel with the NASD, now known as FINRA, has practiced in this area of the law for more than 35 years. We would like to discuss the possibility of your retaining our firm to represent you in an arbitration action.
There is no charge for an evaluation of your case. Further, we handle our cases on a contingency fee basis. This means that unless we recover money for you, we charge no attorney’s fee. Unless you recover any money, you pay us nothing, not even the costs and expenses which the firm will advance on your behalf. Finally, the filing of such a case should not affect your ownership of these investments in any way.
If you incurred losses on your investment in Edge Therapeutics (EDGE) and/or other high-risk investments and would like your case evaluated by a securities attorney (again, there is no charge for an evaluation and all cases are handled on a purely contingency fee basis), please contact us.
Keywords: Edge Therapeutics, EDGE, Biotechnology, FINRA, SEC, Fraud, Attorney, Broker, Brokerage, Firm, Brokerage Firm, Invest, Lawyer, Securities Lawyer, Goodman and Nekvasil, Nekvasil, Goodman, Investor, Investment, Financial, Financial Services, Securities